TransCode Therapeutics, Inc. (RNAZ)

NASDAQ: RNAZ · IEX Real-Time Price · USD
1.29
0.00 (0.00%)
At close: Aug 15, 2022 3:59 PM
1.36
+0.07 (5.43%)
After-hours: Aug 15, 2022 5:48 PM EDT
0.00%
Market Cap 16.74M
Revenue (ttm) n/a
Net Income (ttm) -5.83M
Shares Out 12.98M
EPS (ttm) -0.55
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 38,311
Open 1.35
Previous Close 1.29
Day's Range 1.28 - 1.40
52-Week Range 1.13 - 5.28
Beta n/a
Analysts Buy
Price Target 10.20 (+690.7%)
Earnings Date Aug 22, 2022

About RNAZ

TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. The company's products in preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. Its cancer agnostic programs comprise TTX-RIGA, an RNA"based a... [Read more...]

Industry Biotechnology
IPO Date Jul 9, 2021
Employees 8
Stock Exchange NASDAQ
Ticker Symbol RNAZ
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for RNAZ stock is "Buy." The 12-month stock price forecast is 10.2, which is an increase of 690.70% from the latest price.

Price Target
$10.2
(690.70% upside)
Analyst Consensus: Buy
Stock Forecasts

News

TransCode Therapeutics Reports Second Quarter 2022 Results; Provides Business Update

BOSTON, Aug. 15, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported finan...

TransCode Therapeutics and MD Anderson Announce Strategic Alliance to Advance RNA Therapies for Oncology

BOSTON and HOUSTON, Aug. 02, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (“TransCode” or the “Company”), the RNA oncology company, and The University of Texas MD Anderson Cancer...

TransCode Therapeutics Announces Expansion of Global RNA Oncology Patent Portfolio

BOSTON, July 11, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to defeating cancer using RNA therapeutics, today announced extension of its int...

TransCode Therapeutics to Participate at BIO International Convention

BOSTON, June 09, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) today announced that it will be attending and presenting at the BIO International Convention to be held June 13-16 i...

TransCode Therapeutics Receives National Institutes of Health (NIH) Notice of Award

Funding is part of a 2021 Fast-Track Small Business Innovation Research (SBIR) grant to Support Clinical Development of First-in-Class Therapy for Advanced Solid Tumors

TransCode Therapeutics To Participate at H.C. Wainwright Global Investment Conference

BOSTON, May 20, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) today announced that it will be presenting at the H.C. Wainwright Global Investment Conference. The in-person venue f...

TransCode Therapeutics Acquires Option for Radiotheranostic Technology

BOSTON, May 19, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to defeating cancer using RNA therapeutics, is pleased to announce its execution ...

TransCode Therapeutics Reports First Quarter 2022 Results; Provides Business Update

BOSTON, May 16, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to defeating cancer using RNA therapeutics, today reported financial results for ...

TransCode Therapeutics' CTO, Dr. Zdravka Medarova, to Moderate 7th Annual RNA Medicine Symposium

Dr. Medarova will present at the 3rd Annual RNAi-Based Therapeutics Summit on April 20 Dr. Medarova will present at the 3rd Annual RNAi-Based Therapeutics Summit on April 20

TransCode Therapeutics Reports 2021 Results; Provides Business Update

Company to host investor update call Thursday, April 7, at 4:30 p.m. ET Company to host investor update call Thursday, April 7, at 4:30 p.m. ET

TransCode Therapeutics Interview to Air on Bloomberg U.S. on the RedChip Money Report®

BOSTON, March 25, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a biopharmaceutical company committed to defeating cancer using RNA therapeutics, today announced that an intervie...

TransCode Therapeutics Announces Article Published in the Journal Cancers Detailing the Potential for Short RNA-based...

BOSTON, March 23, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to defeating cancer using RNA therapeutics, in collaboration with teams from, M...

CORRECTION --TransCode Therapeutics

BOSTON, Feb. 10, 2022 (GLOBE NEWSWIRE) -- In a release issued under the headline "TransCode Therapeutics to Present at 2020 BIO CEO & INVESTOR CONFERENCE" earlier today by TransCode Therapeutics, Inc. (...

TransCode Therapeutics to Present at 2020 BIO CEO & INVESTOR CONFERENCE

BOSTON, Feb. 10, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) today announced that it will be presenting at the 2022 BIO CEO & Investor Conference.

TransCode Therapeutics To Participate at H.C. Wainwright BioConnect Conference

BOSTON, Jan. 06, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) today announced that it will be attending and presenting at the H.C. Wainwright BioConnect Conference. TransCode's C...

TransCode Therapeutics To Participate at MedInvest Oncology Investor Conference

BOSTON, Dec. 06, 2021 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) today announced that it will be attending and presenting at the MedInvest Oncology Investor Conference. TransCode's ...

TransCode Therapeutics Reports Business Progress and Third Quarter 2021 Financial Results

BOSTON--(BUSINESS WIRE)--TransCode Therapeutics, Inc. (Nasdaq: RNAZ), an RNA oncology company created on the belief that cancer can be defeated through the intelligent design and effective delivery of R...

TransCode Therapeutics Announces Participation in the Q4 Virtual Investor Summit

Boston, Massachusetts--(Newsfile Corp. - November 9, 2021) - TransCode Therapeutics, Inc. (NASDAQ: RNAZ) today announced that it will be attending and presenting at the Q4 Virtual Investor Summit. Trans...

TransCode Therapeutics Appoints Zdravka Medarova, Ph.D., as Chief Technology Officer

BOSTON--(BUSINESS WIRE)--TransCode Therapeutics, Inc. (TransCode) (Nasdaq: RNAZ), an emerging RNA oncology company created on the belief that cancer can be defeated through the intelligent design and ef...

RNAZ Stock Alert: The Breast Cancer Study News Sending TransCode Therapeutics Soaring Today

TransCode Therapeutics (RNAZ) stock is rocketing higher on Thursday as investors react to positive news from a breast cancer study. The post RNAZ Stock Alert: The Breast Cancer Study News Sending TransC...

Here's why TransCode Therapeutics stock is up about 65% on Thursday

Shares of TransCode Therapeutics Inc (NASDAQ: RNAZ) climbed by 65% on Thursday morning as the oncology company said in its press release that the preclinical research supporting its lead candidate, TTX-...

Why Are TransCode Therapeutics Shares Shooting Higher On Thursday?

TransCode Therapeutics Inc (NASDAQ: RNAZ) is trading higher after preclinical research supporting its lead candidate, TTX-MC138, was published in Cancer Nanotechnology.  Related:   TransCode Therapeutic...

TransCode Therapeutics Announces Publication in Cancer Nanotechnology of Preclinical Data Supporting Therapeutic Pote...

BOSTON--(BUSINESS WIRE)--TransCode Therapeutics, Inc. (Nasdaq: RNAZ), an emerging RNA oncology company created on the belief that cancer can be defeated through the intelligent design and effective deli...

TransCode Therapeutics Reports Business Progress and Second Quarter 2021 Financial Results

BOSTON--(BUSINESS WIRE)--TransCode Therapeutics, Inc. (Nasdaq: RNAZ), an emerging RNA oncology company, created on the belief that cancer can be defeated through the intelligent design and effective del...

TransCode Therapeutics Secures NIH Funding To Support Its Lead Program Development

TransCode Therapeutics Inc (NASDAQ: RNAZ) has received a Fast-Track Small Business Innovation Research (SBIR) grant from the NIH to support developing TTX-MC138. TTX-MC138 is TransCode's lead therapeuti...